Standardizing cancer biomarkers criteria: Data elements as a foundation for a database. Inflammatory mediator/M-CSF as model marker

Cell Biochemistry and Biophysics

Volumn 47, Issue 2, 2007, Pages 187-198

  Khatami, Mahin ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer biomarkers; Chemoprevention; Data elements; Database; Early detection; Inflammatory mediators; Macrophage colony stimulating factor; Oncology; Standardizing biomarkers criteria; Therapy

Indexed keywords

BIOLOGICAL MARKER; COLONY STIMULATING FACTOR 1; CYTOKINE; TUMOR MARKER;

ANIMAL; BIOLOGY; HUMAN; INFLAMMATION; METABOLISM; METHODOLOGY; NEOPLASM; ONCOLOGY; PROTEIN DATABASE; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STANDARD; THEORETICAL MODEL; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL MARKERS; COMPUTATIONAL BIOLOGY; CYTOKINES; DATABASES, PROTEIN; HUMANS; INFLAMMATION; MACROPHAGE COLONY-STIMULATING FACTOR; MEDICAL ONCOLOGY; MODELS, THEORETICAL; NEOPLASMS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34548329142     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-007-0003-z     Document Type: Review

References (51)

1. Al-Sarireh, B., & Eremin, O. (2000). Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth. Journal of Royal College of Surgeons of Edinburgh, 45(1), 1-16.
2. Alessandro, R., Belluco, C., & Kohn, E. C. (2005). Proteomic approaches in colon cancer: promising tools for new cancer markers and drug target discovery. Clinical Colorectal Cancer, 4(6), 396-402.
3. Bastian, P. J., Yegnasubramanian, S., Palapattu, G. S., & Rogers, C. G., et al. (2004). Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. European Urology, 46, 698-708.
4. Bekaert, S., De Meyer, T., & Van Oostveldt, P. (2005). Telomerase attrition as ageing biomarker. Anticancer Research, 25, 3011-3021.
5. Blackburn, E. H. (2005) Telomerase and cancer: Kirk A. London-AACR prize for basic cancer research lecture. Molecular Cancer Research, 3, 477-482.
6. Bonassi, S., Ugolini, D., Kirsch-Volders, M., & Stromberg, U., et al. (2005). Human population studies with cytogenetic biomarkers: Review of the literature and future perspectives. Environmental and Molecular Mutagenesis, 45, 258-270.
7. Collado, M., Gil, J., Efeyan, A., Guerra, C., & Schuhmacher, A. J., et al. (2005). Tumour biology senescence in premalignant tumours. Nature, 436(7051), 636-7.
8. Etzioni, R., Urban, N., & Ramsey, S., et al. (2003). The case for early detection. Nature Reviews Cancer, 3, 243-252.
9. Ferrandina, G., Ranelletti, F. O., Legge, F., & Lauriola, L., et al. (2003). Prognostic role of the ratio between cyclooxygenase-2 in tumor and stroma compartments in cervical cancer. Clinical Cancer Research, 9(12), 4324-4331.
10. Il'yasova, D., Colber, L. H., Harris, T. B., & Newman, A. B., et al. (2005). Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiology, biomarkers, & Prevention, 14(10), 2413-2417.
11. Ito, Y, Suzuki, K, & Tamakoshi, K, et al. (2005). Colorectal cancer and C-reactive protein levels: a case-control study nested in JACC Study. Journal of Epidemiology, Suppl. 2, S185-189.
12. Johnson, M. D., Oberst, M. D., Lin, C. Y., & Dickson, R. B. (2005). Possible role of matripase in the diagnosis of ovarian cancer. Expert Review of Molecular Diagnostics, 3, 331-338.
13. Kelloff, G. J., Bast, R. C. Jr, & Coffey, D. S., et al. (2004). Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clinical Cancer Research, 10, 3881-3884.
14. Khatami M. (2005). Standardizing criteria on cancer biomarkers as foundation of a database: Creating a common language (data elements) for cancer biomarkers tracking and utilization for professionals in oncology research. Federal Register July 22, 70: (No.140), 42350-42351.
15. Khatami, M. (2005). Developmental phases of inflammation-induced massive lymphoid hyperplasia and extensive changes in epithelium in an experimental model of allergy. Implications for a direct link between inflammation and carcinogenesis. American Journal of Therapeutics, 12, 117-128.
16. Khatami, M. (2005). Cyclooxygenase inhibitor Ketorolac or mast cell stabilizers: immunological challenges in cancer therapy. Clinical Cancer Research, 11, 1350-1352.
17. Khatami, M. (2006). Focusing on Promotion of Innate Immune Response System for Therapy, Diagnosis and Prevention of Tumor/Cancer. 4th Annual Cytokines and Inflammation Conference, San Diego, CA, (Abstract) January 30-31.
18. Kojima, M., Morisaki, T., & Izuhara, K., et al. (2000). Lipopolysaccharide increases cyclo-oxygenase-2 expression in a colon carcinoma cell line through nuclear factor-kappa B activation. Oncogene, 19(9), 1225-1231.
19. Koopmann, J., Buckhaults, P., Brown, D. A., Zahurak, M. L., et al. (2004). Serum Macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clinical Cancer Research, 10, 2386-2392.
20. Le Meur, Y., Leprivey-Lorgeot, V., Mons, S., & Jose, M., et al. (2004). Serum levels of macrophage-colony stimulating factor (M-CSF): A marker of kidney allograft rejection. Nephrology, Dialysis, Transplantation, 19, 1862-1865.
21. Lee, M. S., Kim, T. Y., & Kim, Y. B., et al. (2005). The signaling network of transforming growth factor beta 1, protein kinase C delta, and integrin underlies the spreading and invasiveness of gastric carcinoma cells. Molecular Cell Biology, 25, 6921-6936.
22. Lepor, H. (2004). Radical prostectomy: Status and opportunities for improving outcomes. Cancer Investigation, 22, 435-444.
23. Letterio, J. J. (2005). TGF-beta signaling in T cells: Roles in lymphoid and epithelial neoplasia. Oncogenes, 24, 5701-5712.
24. Lieberman, R. (2004). Evidence-based medical perspectives: The evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for intervention in men with different clinical risk states for the prevention and progression of prostate cancer. American Journal of Therapeutics, 11, 501-506.
25. Lima, S. C. (2002). Expression of Fas ligand and sFas ligand in human gastric adenocarcinomas. Oncology Reports, 9, 103-107.
26. Lima, Y. P. (2005). Mining the tumor phosphoproteome for cancer markers, Clinical Caner Research, 11, 3163-3169.
27. Lobdell, D.T, & Mendola, P. (2005). Development of a biomarkers database for the National Children's Study. Toxicology and Applied Pharmacology, 206(2), 269-273.
28. McCubrey, J. A., Shelton, J. G., Steelman, L. S., & Franklin, R. A., et al. (2004). Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells. Oncogene, 23(47), 7810-7820.
29. Morimoto, L. M., Newcomb, P. A., White, E., Bigler, J., & Potter, J. D. (2005). Variation in plasma insulin-like growth factor-1, insulin-like growth factor binding protein-3 genetic factors. Cancer Epidemiology Biomarkers & Prevention, 14(6), 1394-1401.
30. Mroczkoa, B., Szmitkowski, M., & Niklinski, J. (2001). Granulocyte-Colony stimulating factor and macrophage-colony stimulating factor in patients with non-small-cell lung cancer. Clinical Chemistry and Laboratory Medicine, 39(5), 374-379.
31. Mroczkob, B., Szmitkowski, M., & Okulczyk, B. (2002). Granulocyte-colony stimulating factor (G-CSF) and macrophage colonystimulating factor (M-CSF) in colorectal cancer patients. Clinical Chemistry and Laboratory Medicine, 40(4), 351-355.
32. Mroczkoc, B., Szmitkowski, M., Wereszcynska-Siemiatkowska, U., & Jurkowska, G. (2004). Stem cell factor and macrophagecolony stimulating factor in patients with pancreatic cancer. Clinical Chemistry and Laboratory Medicine, 42(3), 256-260.
33. Mroczkod, B., & Szmitkowski, M. (2004). Hematopoietic cytokines as tumor markers. Clinical Chemistry and Laboratory Medicine, 42(12), 1347-1354.
34. Mroczkoe, B., Szmitkowski, M., Wereszynska-Siemiatkowska, U., & Okulczyk, B. (2005). Stem cell factor (SCF) and interleukin 3 (IL-3) in the sera of patients with colorectal cancer. Digestive Diseases and Sciences, 50(6), 1019-1024.
35. Murakami, M., Sasaki, T., & Miyata, H., et al. (2004). Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma. Oncology Reports, 11, 1183-1186.
36. Osada, M., Park, H. L., & Nagakawa, Y et al. (2005). Differential recognition of response elements determines target gene specificity for p53 and p63. Molecular Cell Biology, 25, 6077-6089.
37. Qin, L. X., & Tang, Z. Y. (2004). Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. Journal of Cancer Research and Clinical Oncology, 130(9), 497-513.
38. Rak, J., Milsom, C., May, L., Klement, P., & Yu, J. (2006). Tissue factor in cancer, angiogenesis The molecular link between genetic tumor progression, tumor neovascularization and cancer coagulopathy. Seminars in Thrombosis Hemostasis, 2(1), 54-70.
39. Rentsch, C. A., Cecchini, M. G., Schwaninger, R., & Germann, M., et al. (2006). Differential expression of TGFbeta-stimulated clone 22 in normal prostate and prostate cancer. International Journal of Cancer, 118, 899-906.
40. Rogers, C. G., Yan, G., Zha, S., & Gonzales, M. L., et al. (2004). Prostate cancer detection on urinolysis for alpha methylacyl coenzyme a racemase protein. Journal of Urology, 72, 1501-1503.
41. Sapi, E. (2004). The role of CSF-1 in normal physiology of mammary gland breast cancer: An update. Experimental Biology and Medicine (Maywood), 229(1), 1-11.
42. Schatzkin, A. (2005). Problems with using biomarkers as surrogate end points for cancer: a cautionary tale. Recent Results Cancer Research, 166, 89-98.
43. Shimizu, M., Kondo, M., Ito, Y., Kume, H., & Suzuki, R., et al. (2004). Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients. Cancer Detection and Prevention, 29(2), 175-180.
44. Spentzos, D., Levine, D. A., & Kolia, S., et al. (2005). Unique gene expression profile based on pathologic response in epithelial ovarian cancer. Journal of Clinical Oncology, 23(31), 791-798.
45. Suzuki, M., Tamura, N., Kobayashi, H., Ohwada, M., et al. (2000). Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary. Gynecologic Oncology, 77, 405-409.
46. Tanimoto, H., Shigemasa, K., Tian, X., & Gu, L., et al. (2005). Transmembrane serine protease TADG-15 (ST14/Matripase/MTSP1): expression and prognostic value in ovarian cancer. Brtish Journal of Cancer, 92, 278-283.
47. Tas, F., Duranyilidiz, D., & Argon, A., et al. (2005). Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Medical Oncology, 22(4), 353-358.
48. Van Marck, V., Stove, C., Van Den Bossche, K., et al. (2005). P-cadherin promotes cell-cell adhesion and counteracts invasion in human melanoma. Cancer Research, 65(19), 8774-8783.
49. Woodford-Richens, K. L., Rowan, A. J., Gorman, P., & Halford, S., et al. (2001). SMAD4 mutations in colorectal cancer probable occur before chromosomal instability, but after divergence of the microsatellite instability pathways. Proceedings of National Academy of Sciences, 98(17), 9719-9723.
50. Wu, X., Zhao, Y., Kemp, B. L., Amos, C. L., Sicilliano, M. J., & Spitz, M. R. (1998). Chromosome 5 aberrations and genetic predisposition to lung cancer. International Journal of Cancer, 79(5), 490-493.
51. Wu, X., Ivanova, G., Merup, M., & Jansson, M., et al. (1999) Molecular analysis of the human chromosome 5q13.3 region in patients with hairy cell leukemia and identification of tumor suppressor gene candidates. Genomics, 60(2), 161-171.